Scientific publications

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

Jul 26, 2023 | Magazine: International Journal of Molecular Sciences

Miriam Longo  1   2 , Daniel Jericó  1 , Karol M Córdoba  1 , José Ignacio Riezu-Boj  3   4 , Raquel Urtasun  5 , Isabel Solares  6 , Ana Sampedro  1 , María Collantes  4   7   8 , Ivan Peñuelas  4   7   8 , María Jesús Moreno-Aliaga  3   4   9 , Matías A Ávila  1   4   10 , Elena Di Pierro  2 , Miguel Barajas  5 , Fermín I Milagro  3   4   9 , Paola Dongiovanni  2 , Antonio Fontanellas  1   4   10


Abstract

Acute intermittent porphyria (AIP) is a metabolic disorder caused by mutations in the porphobilinogen deaminase (PBGD) gene, encoding the third enzyme of the heme synthesis pathway.

Although AIP is characterized by low clinical penetrance (~1% of PBGD mutation carriers), patients with clinically stable disease report chronic symptoms and frequently show insulin resistance.

This study aimed to evaluate the beneficial impact of nutritional interventions on correct carbohydrate dysfunctions in a mouse model of AIP that reproduces insulin resistance and altered glucose metabolism. The addition of spores of Bacillus coagulans in drinking water for 12 weeks modified the gut microbiome composition in AIP mice, ameliorated glucose tolerance and hyperinsulinemia, and stimulated fat disposal in adipose tissue.

Lipid breakdown may be mediated by muscles burning energy and heat dissipation by brown adipose tissue, resulting in a loss of fatty tissue and improved lean/fat tissue ratio. Probiotic supplementation also improved muscle glucose uptake, as measured using Positron Emission Tomography (PET) analysis.

In conclusion, these data provide a proof of concept that probiotics, as a dietary intervention in AIP, induce relevant changes in intestinal bacteria composition and improve glucose uptake and muscular energy utilization. Probiotics may offer a safe, efficient, and cost-effective option to manage people with insulin resistance associated with AIP.

CITATION  Int J Mol Sci. 2023 Jul 26;24(15):11938. doi: 10.3390/ijms241511938

Our authors